Key Points
- CEO Daniel O’Day sold 10,000 shares on Feb. 27 at an average price of $144.79 (~$1.45M), trimming his stake to 642,308 shares (a 1.53% reduction) — part of a recent pattern of insider sales that included two 115,640‑share disposals in Jan/Feb.
- Strategic catalyst: Gilead agreed to buy Arcellx for about $7.8 billion to bolster its oncology and cell‑therapy pipeline, a move viewed as the primary near‑term catalyst while analysts have raised price targets and maintain a consensus "Moderate Buy" (~$156.72 target).
- Solid results and a bigger payout: Gilead beat the quarter with $1.86 EPS on $7.93B revenue, set FY2026 guidance at $8.45–$8.85 EPS, and raised its quarterly dividend to $0.82 (annualized $3.28, ~2.2% yield).
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the transaction, the chief executive officer owned 642,308 shares in the company, valued at $92,999,775.32. The trade was a 1.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Daniel Patrick O'day also recently made the following trade(s):
- On Thursday, February 5th, Daniel Patrick O'day sold 115,640 shares of Gilead Sciences stock. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00.
- On Wednesday, January 28th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $139.89, for a total value of $1,398,900.00.
- On Friday, January 23rd, Daniel Patrick O'day sold 115,640 shares of Gilead Sciences stock. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00.
- On Monday, December 29th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $124.83, for a total transaction of $1,248,300.00.
Gilead Sciences Stock Performance
Shares of GILD stock opened at $150.03 on Tuesday. The firm has a market cap of $186.25 billion, a price-to-earnings ratio of 22.16, a P/E/G ratio of 1.95 and a beta of 0.36. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The firm's 50-day simple moving average is $136.62 and its two-hundred day simple moving average is $125.06.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts' consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the prior year, the firm earned $1.90 EPS. The company's revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a $0.82 dividend. The ex-dividend date is Friday, March 13th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences's dividend payout ratio is presently 46.68%.
Gilead Sciences News Roundup
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead agreed to buy Arcellx for about $7.8 billion in cash, expanding Gilead’s footprint in oncology and cell therapy and reducing its reliance on the HIV franchise — a strategic diversification story that can support a higher multiple if the assets progress. The deal is being viewed as the primary near-term catalyst. Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance
- Neutral Sentiment: Analyst/market commentary highlighting Gilead as a momentum stock may sustain investor interest, but such pieces typically reinforce sentiment rather than change fundamentals. Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
- Neutral Sentiment: Gilead Foundation announced a $12M award to support HIV prevention and community health workers — positive PR and aligns with long-term mission, but immaterial to near-term financials. Gilead Foundation Awards $12 Million
- Neutral Sentiment: Reported short-interest data is effectively meaningless (showing 0 shares / 0 days), so it likely isn’t driving price action. No actionable short-squeeze signal present.
- Negative Sentiment: CEO Daniel O’Day sold 10,000 shares (~$1.45M) in late February. Insider selling can spook some investors even if sales are common for liquidity/tax reasons; this is a modest percentage of his holdings. SEC Form 4 — Insider Sale
Hedge Funds Weigh In On Gilead Sciences
Institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC lifted its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth $215,000. Sivia Capital Partners LLC grew its position in Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock worth $464,000 after acquiring an additional 602 shares in the last quarter. GHP Investment Advisors Inc. grew its position in Gilead Sciences by 1.0% in the second quarter. GHP Investment Advisors Inc. now owns 12,513 shares of the biopharmaceutical company's stock worth $1,387,000 after acquiring an additional 124 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. raised its position in Gilead Sciences by 32.1% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 5,247 shares of the biopharmaceutical company's stock valued at $582,000 after purchasing an additional 1,276 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several research firms have commented on GILD. Daiwa Securities Group upped their price objective on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an "outperform" rating in a report on Wednesday, February 25th. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an "outperform" rating in a research report on Monday, January 26th. Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $103.00 to $118.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 11th. HSBC boosted their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a "hold" rating in a report on Wednesday, December 10th. Finally, Cantor Fitzgerald raised their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock an "overweight" rating in a report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $156.72.
Check Out Our Latest Research Report on Gilead Sciences
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
